The funds will aid in the development of compounds that act on the motor circuitry that is compromised in Parkinson’s disease (PD) through the modulation of a receptor target.
Further studies on the functional role of the biological target will lead to the advancement of the compounds through preclinical development.
MJFF chief executive officer Todd Sherer said Levodopa is still the standard of care for people with Parkinson’s, but the side effects of levodopa treatment remain one of the challenging aspects of living day to day with the disease.
"For this reason, developing improved symptomatic treatments that limit dyskinesia is a priority for our Foundation," Sherer added.
Envoy’s bacTRAP technology enables the identification of new drug targets selectively expressed in brain circuits of therapeutic interest, thereby reducing the activity in circuits which may trigger unwanted side effects.